

Amendments to the Claims:

1. (currently amended) A recombinant nucleotide construct composed of the sequence of SEQ ID NO: 1 ~~or a species equivalent and encoding a mutated human~~ prolactin, wherein the expression of the sequence results in a mimic of a phosphorylated ~~human~~ prolactin ~~corresponding to a selected species~~, the mimic being capable of antagonizing growth promoting effects of non-phosphorylated ~~human~~ prolactin ~~in the selected species~~, the mimic being mutated by an aspartate or glutamate residue substitution at serine 179 or its selected species equivalent.
2. (canceled)
3. (currently amended) The nucleotide sequence as in claim 1 wherein the serine is mutated by ~~an aspartate or a glutamate~~ residue substitution.
4. (previously presented) The nucleotide sequence as in claim 1 wherein the serine mutation is by an aspartate residue substitution.
5. (original) A construct comprising the nucleotide of claim 3 or 4 operatively linked with an expression vector.
6. (original) The construct as in claim 5 wherein the expression vector is mammalian, viral or bacterial.
9. (previously presented) A composition comprising:
a human phosphorylated prolactin mimic, the mimic in an amount effective to antagonize growth promoting effects of non-phosphorylated human prolactin, the mimic being expressible by SEQ ID NO:1, being mutated at serine 179 and being substantially free of non-phosphorylated human prolactin; and
a pharmaceutically suitable carrier in which the mimic is admixed.
10. (original) The composition as in claim 9 wherein the serine 179 is substituted by an aspartate or glutamate residue.

11. (original) The composition as in claim 9 wherein the serine 179 is substituted by an aspartate residue.